



Beginning Q2 2024, Pfizer is communicating a change in acceptable covered entity inventory management processes for certain sterile injectable products that are being issued new National Drug Code (“NDC”) numbers. Pfizer has requested that the Health Resources and Services Administration (“HRSA”) post this notice on its website to notify 340B covered entities that the existing NDCs for the products listed below are being transferred to new NDCs.

Existing NDC	New NDC	Description	New NDC Effective Date
00009-7529-05	00009-0082-02	Camptosar™ (Irinotecan Hydrochloride Injection, USP) 300 mg/15 mL (20 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial	Jun-2024
00009-7529-04	00009-7529-10	Camptosar™ (Irinotecan Hydrochloride Injection, USP) 40 mg/2 mL (20 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial	Aug-2024
00069-3030-20	00069-0358-20	DOXOrubicin Hydrochloride Injection, USP 10 mg/5 mL (2 mg/mL) Onco-Tain® Single Dose Vial	Oct-2024
00069-3031-20	00069-0277-02	DOXOrubicin Hydrochloride Injection, USP 20 mg/10 mL (2 mg/mL) Onco-Tain® Single Dose Vial	Sep-2024
00069-3034-20	00069-1542-20	DOXOrubicin Hydrochloride Injection, USP 200 mg/100 mL (2 mg/mL) Onco-Tain® Multiple Dose Vial	Aug-2024
00069-3032-20	00069-0343-02	DOXOrubicin Hydrochloride Injection, USP 50 mg/25 mL (2 mg/mL) Onco-Tain® Single Dose Vial	Dec-2024
00009-5093-01	00009-5093-10	Ellence™ (epirubicin hydrochloride Injection, USP) 200 mg/mL 100 mL (2 mg/mL) Onco-Tain® Single Dose Vial	Dec-2024
00013-2586-91	00013-2586-10	Idamycin PFS® (idarubicin hydrochloride injection) 10 mg/10 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial	Apr-2024
00013-2596-91	00013-2596-20	Idamycin PFS® (idarubicin hydrochloride injection) 20 mg/20 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial	Apr-2024
00013-2576-91	00013-2576-05	Idamycin PFS® (idarubicin hydrochloride injection) 5 mg/50 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial	Sep-2024

Existing NDC	New NDC	Description	New NDC Effective Date
00409-3793-01	00409-3793-25	Ketorolac Tromethamine Injection, USP 15 mg/mL Single Dose Glass Fliptop Vial	Sep-2024
00409-3795-01	00409-3795-25	Ketorolac Tromethamine Injection, USP 30 mg/mL Single Dose Glass Fliptop Vial	Nov-2024
00409-3796-01	00409-3796-25	Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL) Single Dose Glass Fliptop Vial	Jun-2024
00409-2305-17	00409-0001-25	Midazolam Injection, USP CIV 2 mg/2mL (1 mg/mL) Single Dose Glass Fliptop Vial	Dec-2024

As noted, the table above includes both the existing and new NDCs for the referenced products. Because the new NDCs are for the same product (drug, dosage form, and package size) and have the same 340B price as the corresponding old NDC, Pfizer will allow eligible 340B covered entities that use a HRSA 340B compliant inventory replenishment model to count accumulations of the existing NDCs toward replenishment of equal quantities of the corresponding new NDCs.

This change in Pfizer process will apply prospectively to Pfizer’s sterile injectable products when new NDCs are for the same product (drug, dosage form, and package size) and have the same 340B price as the corresponding old NDC.

If there are any questions, please contact [PICustomerService@pfizer.com](mailto:PICustomerService@pfizer.com) or 844-646-4398.